APA (7th ed.) Citation

YC, J., J, G., SH, L., X, D., CY, W., LH, L., . . . YL, W. (2025). Vincamine ameliorates hepatic fibrosis via inhibiting S100A4-mediated farnesoid X receptor activation: Based on liver microenvironment and enterohepatic circulation dependence. British journal of pharmacology, 182(11), 2447. https://doi.org/10.1111/bph.17471

Chicago Style (17th ed.) Citation

YC, Jiang, Guo J, Liu SH, Dai X, Wang CY, Lian LH, Cui ZY, Nan JX, and Wu YL. "Vincamine Ameliorates Hepatic Fibrosis via Inhibiting S100A4-mediated Farnesoid X Receptor Activation: Based on Liver Microenvironment and Enterohepatic Circulation Dependence." British Journal of Pharmacology 182, no. 11 (2025): 2447. https://doi.org/10.1111/bph.17471.

MLA (9th ed.) Citation

YC, Jiang, et al. "Vincamine Ameliorates Hepatic Fibrosis via Inhibiting S100A4-mediated Farnesoid X Receptor Activation: Based on Liver Microenvironment and Enterohepatic Circulation Dependence." British Journal of Pharmacology, vol. 182, no. 11, 2025, p. 2447, https://doi.org/10.1111/bph.17471.